Effect of polaprezinc on healing of acetic acid-induced stomatitis in hamsters.
OBJECTIVE
The purpose of this work was to investigate the potential effectiveness of polaprezinc in the treatment of stomatitis. Its effect on oral mucous membrane lesions was studied focusing on acetic acid-induced stomatitis in an animal model.


METHODS
Stomatitis was induced in hamsters by local injection of 30 microL of 10% acetic acid solution into both cheek pouches. Change of the size of the acetic acid-induced white lesion caused by polaprezinc injection was compared with that of control (water injection). The process of healing of damaged membrane was also investigated histopathologically. Selective adhesion of polaprezinc on mucous membrane was studied using color development by complexation between zinc and dithizone.


RESULTS
On day 4 after acetic acid injection, round white lesions were observed in the central area of both pouches. Observation on days 7, 10, and 14 showed that the size of the lesions decreased with time. Comparison with the control group of animals, in which healing took place naturally, showed that daily administration of polaprezinc (10 mg/kg) applied to the cheek pouches significantly promoted healing of the lesion from day 7 onward. Histopathological investigation of the mucous membrane in the cheek pouches 7 days after the induction of stomatitis by acetic acid injection showed thickening, and cell damage was evident. In the group of animals treated with polaprezinc, the thickening of the mucous membrane was less than that in animals of the group receiving no treatment and regeneration of damaged tissue was observed after 6 days of polaprezinc treatment.


CONCLUSIONS
Polaprezinc is an effective treatment in this animal model of acetic acid-induced stomatitis. This suggests that the drug may be useful in promoting healing of stomatitis in the clinical setting. Extrapolating these to humans suggests that the drug has healing effect to severe stomatitis induced by anticancer drug therapy.
Katayama
S
S
Department of Pharmacy, Medical School Hospital, Sendagi 1-1-5 Bunkyo-ku, Tokyo 113-8602, Japan. Katayama_Sirou/hosp_pha@nms.ac.jp
Nishizawa
K
K
Hirano
M
M
Yamamura
S
S
Momose
Y
Y
D019342:Acetic Acid / Q000633:toxicity; D000268:Adhesiveness; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002336:Carnosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002610:Cheek; D006224:Cricetinae; D004195:Disease Models, Animal; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D013280:Stomatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D017967:Zinc Compounds
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D002336:Carnosine; D019342:Acetic Acid